LONG-ACTING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISM MITIGATES INFLAMMATION AND FIBROSIS IN MODELS OF NASH AND BILIARY FIBROSIS

被引：0
|
作者：
Wang, X. -Y. [1 ]
Weng, S. -Y. [1 ]
Kim, Y. O. [1 ]
Klein, T. [2 ]
Schuppan, D. [1 ,3 ]
机构：
[1] Inst Translat Immunol, Mainz, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[3] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA
来源：
JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(14)60791-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P629
引用
收藏
页码：S278 / S278
页数：1
相关论文
共 50 条
  • [1] DIRECT GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISM AMELIORATES STEATOHEPATITIS AND FIBROSIS IN MODELS OF NASH AND BILIARY FIBROSIS VIA REGULATION OF LIVER MACROPHAGE INFILTRATION AND ACTIVATION
    Wang, X. -Y.
    Weng, S. -Y.
    Klein, T.
    Kim, Y. O.
    Schuppan, D.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S707 - S707
  • [2] A long-acting GLP-1 agonist exenatide suppresses inflammation and fibrosis in models of NASH and biliary fibrosis
    Wang, Xiao-Yu
    Weng, Shih-yen
    Klein, Thomas
    Kim, Yong Ook
    Schuppan, Detlef
    HEPATOLOGY, 2013, 58 : 585A - 586A
  • [3] Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
    Uccellatore, Annachiara
    Genovese, Stefano
    Dicembrini, Ilaria
    Mannucci, Edoardo
    Ceriello, Antonio
    DIABETES THERAPY, 2015, 6 (03) : 239 - 256
  • [4] Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
    Annachiara Uccellatore
    Stefano Genovese
    Ilaria Dicembrini
    Edoardo Mannucci
    Antonio Ceriello
    Diabetes Therapy, 2015, 6 : 239 - 256
  • [5] Long-acting glucagon-like peptide-1 receptor agonist-status December 2018
    Holst, Jens Juul
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (05)
  • [6] Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus
    Hulst, Abraham H.
    Polderman, Jorinde A. W.
    Siegelaar, Sarah E.
    van Raalte, Daniel H.
    DeVries, J. Hans
    Preckel, B.
    Hermanides, Jeroen
    BRITISH JOURNAL OF ANAESTHESIA, 2021, 126 (03) : 567 - 571
  • [7] Discovery of a long-acting glucagon-like peptide-1 analog with enhanced aggregation propensity
    Takeuchi, Mitsuaki
    Okamoto, Masayuki
    Okamoto, Ryuji
    Kinoshita, Hiroshi
    Yamaguchi, Yu
    Watanabe, Nobuhide
    PEPTIDES, 2018, 102 : 8 - 15
  • [8] Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function
    Saraceni C.
    Broderick T.L.
    Drugs in R & D, 2007, 8 (3) : 145 - 153
  • [9] Long acting peptide (LAP™) analogues of glucagon-like peptide-1
    Habi, Abdekrim
    Abran, Daniel
    Peri, Krishna G.
    Brubaker, Patricia
    Abribat, Thierry
    PEPTIDE REVOLUTION: GENOMICS, PROTEOMICS & THERAPEUTICS, 2004, : 623 - 624
  • [10] Pharmacokinetics and Pharmacodynamics of Liraglutide, a Long-Acting, Potent Glucagon-Like Peptide-1 Analog
    Meece, Jerry
    PHARMACOTHERAPY, 2009, 29 (12): : 33S - 42S
12345